Insulin Resistance, Hyperglycemia, and Atherosclerosis
被引:632
|
作者:
Bornfeldt, Karin E.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Washington, Dept Pathol, Diabet & Obes Ctr Excellence, Seattle, WA 98109 USAColumbia Univ, Dept Med, New York, NY 10032 USA
Bornfeldt, Karin E.
[2
]
Tabas, Ira
论文数: 0引用数: 0
h-index: 0
机构:
Columbia Univ, Dept Med, New York, NY 10032 USA
Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA
Columbia Univ, Dept Physiol & Cellular Biophys, New York, NY 10032 USAColumbia Univ, Dept Med, New York, NY 10032 USA
Tabas, Ira
[1
,3
,4
]
机构:
[1] Columbia Univ, Dept Med, New York, NY 10032 USA
[2] Univ Washington, Dept Pathol, Diabet & Obes Ctr Excellence, Seattle, WA 98109 USA
[3] Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA
[4] Columbia Univ, Dept Physiol & Cellular Biophys, New York, NY 10032 USA
Progress in preventing atherosclerotic coronary artery disease (CAD) has been stalled by the epidemic of type 2 diabetes. Further advances in this area demand a thorough understanding of how two major features of type 2 diabetes, insulin resistance and hyperglycemia, impact atherosclerosis. Insulin resistance is associated with systemic CAD risk factors, but increasing evidence suggests that defective insulin signaling in atherosclerotic lesional cells also plays an important role. The role of hyperglycemia in CAD associated with type 2 diabetes is less clear. Understanding the mechanisms whereby type 2 diabetes exacerbates CAD offers hope for new therapeutic strategies to prevent and treat atherosclerotic vascular disease.